Rajendra K. Jangde*, Sulekha Khute, Harish Bhardwaj, Krishna Yadav
The purpose of the paper is actively exploring the feasibility of using nanocarriers in the brain to treat various neurological disorders. These include Parkinson’s disease, schizophrenia, epilepsy, Alzheimer’s disease, brain cancer, multiple sclerosis, depression, cerebral ischemia, and cerebral malaria. Among the various approaches available, nose-to-brain drug targeting remains the most acceptable but difficult challenge due to the complex structure and multiple barriers presented by the CNS. The various nanoformulations including microemulsions, nanoemulsions, polymeric nanoparticles, micelles, solid lipid nanoparticles (SLNs), liposomes, and transferosomes are currently used for their advanced delivery approaches. The nanoformulations are capable of performing the desired functions of the advanced delivery and targeting approaches, i.e., enhancing nasalto- brain delivery and penetration of the drug across the blood–brain barrier (BBB). These formulations are safe, stable, and capable of improving bioavailability and biocompatibility. These nanocarriers offer numerous advantages over conventional drug delivery systems, such as improved targeting and high drug loading capacity. Researchers and scientists worldwide are working tirelessly in various areas of CNS disorders with or without nanoformulations, and it is still an area that needs to be explored. This review focuses on the major approaches of brain targeting, including efficient delivery of the drug across the blood–brain barrier as well as navigation of the nanoformulations to the desired brain site in conjunction with the global prevalence of certain neurological diseases in the current situation.
Keywords: Nanocarriers; BBB; CNS Targeting; Intranasal drug delivery;Neurological disorders
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi